drugset / Trial / NCT04050800

Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety

NCT04050800 ↗

Phase 0 Completed 5 enrolled Weill Medical College of Cornell University
NaSingle-groupOpen-labelBasic science

Summary

This will be a Phase 1, open label, imaging study of radiochemical and radiation safety in healthy volunteers. Using positron emission tomography (PET) and in-line computed tomography (CT), the whole body (WB) biokinetics of Carbon-11 butanol will be quantified with serial scans acquired every 3 minutes for two hours. Vital signs (VS), electrocardiograms (ECGs) and clinical laboratory tests of intrernal organ function will be acquired before and at several timepoints after administration of the radiopharmaceutical. Radiation exposures will be estimated with the MIRD Formalism.

Timeline

Start
2020-09-17
Primary completion
2020-12-29
Completion
2021-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbon 11 Butanol Diagnostic / imaging agent 555 mbq Intravenous